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Background. The major drawback of stent implantation in native human coronary vessels is the 
occurrence of restenosis. Drug-eluting stents significantly reduce restenosis after percutaneous 
coronary intervention (PCI), but may be associated with persistent local inflammation involved in the 
restenosis mechanisms. In this setting coating coronary devices with anti-inflammatory agents 
represents an intriguing alternative to stent-based local drug delivery. The aim of the present study was 
to test in a porcine model the safety and efficacy of a novel Genistein-eluting balloon preceding 
coronary stenting. 
Design. Female piglets underwent PCI in a randomized fashion with either a Genistein-eluting or a 
standard balloon angioplasty, followed in all vessels by bare-metal stent implantation. Pigs were 
sacrificed at different time points to appraise safety (i.e. endothelialization) and efficacy (i.e. anti-
inflammatory and anti-proliferative effects): 1, 4, and 6-8 weeks following PCI.  
Results. Overall analysis was conducted on 14 piglets. Twenty-five bare-metal stents were implanted 
preceded by angioplasty with a conventional balloon in 13 vessels and by the Genistein-eluted balloon 
in 12. No untoward effects were reported in either group. Healing and endothelialization appeared 
universal within four weeks. The Genistein-eluted balloon group disclosed a significant reduction, at 
four weeks from implantation, of the peri-stent inflammatory cells count (mononucleocytes 39±32 vs. 
96±29 per square millimetre, p=0.019. This effect did not clearly translate into a trend towards a 
reduced neointimal hyperplasia at six-eight weeks (0.13±0.11 vs. 0.14±0.09, p=0.835). 
Conclusion. This study provides the first in vivo demonstration of the anti-inflammatory effects of a 
Genistein-eluting balloon in PCI, warranting further research including the combination of a Genistein-
eluting balloon with standard drug-eluting stent. 
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Introduction 
The major drawback of stent implantation in native human coronary vessels is the occurrence of 
restenosis, especially in complex lesion subsets such as diffuse disease and small vessels. As stents 
resist arterial remodelling (1-4), restenosis after stent implantation is principally due to neointimal 
hyperplasia. Although superior to angioplasty alone, the restenosis rates after bare-metal stent 
implantation are as high as 20% to 40% at 6 months. Given this situation the medical community 
devoted, in the latest years, great efforts to perceive alternative approaches to prevent restenosis (5,6). 
Systemic antiproliferative agents (7), coronary brachytherapy (8), contrast medium–antiproliferative 
formulations (9) have been tested. None has contrasted the central role of drug-eluting stents (10,11,12) 
although their long-term results seemingly limited by the delay in healing related to the risk of late 
stent thrombosis and hypersensitivity reactions (13,14,15).  
Inflammation plays a relevant role among the atherosclerosis and restenosis mechanisms, thus the 
attempt of reducing inflammatory signalling holds the potential to attenuate restenosis without 
significantly delaying arterial healing. Recently, although the use of the oral corticosteroid prednisone 
following bare-metal stent deployment has yielded interesting results (16) a dexamethasone-eluting 
stent has failed to prove effective (17). In this setting an angioplasty balloon coated with Genistein, an 
officially approved and clinically safe flavonoid anti-inflammatory agent not presenting major 
cardiovascular side effects or common intolerances may represent the most advanced and possibly 
superior alternative. 
The aim of the present study was to test in a porcine model the safety and efficacy of a novel Genistein-
eluting (18) balloon preceding coronary stenting. Endothelialization, anti-inflammatory and anti-
proliferative effects were appraised at different time points and compared to controls in which the 
coronary stenting was preceded by conventional angioplasty balloon.  
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Materials and methods 
Study design  
Cross-bred young adult female piglets weighting between 35 and 60 kilograms were investigated 
conforming to The Guide for the Care and Use of Laboratory Animals published by the US National 
Institutes of Health (NIH Publication No. 85-23, revised 1996) and current practice guidelines. 
Moreover, the study was approved by the local regulatory committee for animal welfare. Two vessel 
samples within the left circumflex, the left anterior descending and the right coronary artery were 
selected from each animal, unless these targets were small (eg non-dominant right coronary arteries) or 
challenging for stenting (eg tortuosity or anomalous take-off). The selected coronary arteries were then 
compared as tests and controls within the same or separate animals. The decision whether to treat the 
target vessel with a conventional or the Genistein-eluted angioplasty balloon was based on computer-
generated random numbers without blocks. 
The drug-eluting balloon (Sahajanand Medical Technologies Pvt. Ltd., Gujarat, India) constitutes of  a 
biodegradable polymeric matrix (Poly Lactide-co-Glycolide) coated with Genistein (0.7 mg/mm2, 
112.1 µg on each 3.0 * 17 mm balloon). During the procedures related to the delivery of the coated 
balloon catheter 15-20% of the drug is released (within 30 to 40 seconds) in the blood stream; the 
remaining 60-70% of the drug is intended to reach the local target area (product label data).  
In all target vessels the angioplasty was followed by a standard balloon-expandable bare-metal stent 
implantation. The animals were clinically observed every day until one week postoperatively and then 
weekly by a board certified veterinarian. In case of any abnormality, a complete veterinary clinical 
examination and recording was realized. The piglets were sacrificed at one (3 treated segments), four 
(10 treated segments), and within six and eight weeks (12 treated segments) following stent 
implantation (Figure 1). Coronary segments (1 allocated to conventional and 2 allocated to Genistein-
eluted angioplasty balloon) unsuitable for stenting or from piglets dying before the pre-specified time 
point were excluded.  
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Coronary angioplasty and stenting deployment 
The animals were given Atropine sulphate, Xylaxine, and Ketamine and subsequent anaesthesia was 
induced by Thiopentone sodium. Following orotracheal intubation, on ventral recumbence, they were 
given O2-N2O (1:1) and Halothane 1.5% to 2%. Pancuronium bromide was used as muscle relaxant. 
The ventral neck area was then clipped, scrubbed with Povidone soap and prepared with Povidone 
iodine solution based on standard aseptic techniques. Subsequently a 7 French introducer sheath was 
inserted in the common carotid artery, Amplatz 7 or 6 French left coronary catheters were engaged into 
the respective coronaries under full heparinisation (3 mg/Kg of body weight). The coronary arteries 
were imaged by a standard angiographic technique and the target vessel diameters estimated by 
comparison with the angiographic catheter. The conventional or Genistein-eluted angioplasty balloons 
and the bare-metal stents were delivered using the delivery catheters provided by the respective 
manufacturer. Balloon inflations were performed at nominal pressure for 40-50 seconds in both groups. 
The angioplasty was in all cases followed by a standard balloon expandable bare-metal stent 
implantation. Over-stretching ratio was limited within 1:1 and 1:3 balloon-diameter ratio, appraised by 
visual estimation of reference vessel diameter matched with the appropriately sized balloon at nominal 
dilation pressure. The surgical wound was then closed and dressed as per standard technique. Analgesic 
and antibiotic coverage was provided for the five following postoperative days. Antiplatelet and 
anticoagulant therapy was prescribed as listed: clopidogrel hydrochloride 75mg plus aspirin 75mg once 
the day, starting two days before the procedure and maintained up to the end of the study; heparin 
sodium 3mg/Kg of body weight IV bolus started during the implantation and not reversed post 
surgically; two doses of Fraxiparine (0.4ml each) subcutaneously at 12 hours interval post implantation 
until study end.  
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Qualitative and quantitative coronary analysis 
The animals were euthanized by an excess dose of intravenous thiopentone sodium following a 
standard angiographic examination of the target vessels. The gross specimens consisted of the heart 
with the stents in situ. The heart was perfused with formalin 4% for 20 minutes and consequently fixed 
in methyl Carnoy's solution (60%  methanol, 30% clorophormium and 10% glacial acetic acid) for 24 
hours and in pure ethanol for the next 24 hours. The entire segment of the blood vessel with the stent 
was cut at either end from the host vessel and processed. Final inclusion was performed the following 
morning fixing the specimens pretreated in a clorophormium solution for two hours in formalin melted 
at 70°C over night. One hundred mm thick sections were cut perpendicular to the long axis of the 
vessel, at the proximal, mid and distal stent level. The sections were stained with toulidine 
blue/haematoxylin and eosin/VVG. In addition, 10 mm thick sections of proximal and distal segments 
(5 mm from the stent edge) were processed and embedded in paraffin wax and 5 mm thick sections 
were cut and stained with haematoxylin and eosin. Relevant photomicrographs were taken for each 
segment of interest.      
Histomorphometric variables of the target vessels were analyzed by the NIH Image Program (PC 
version Scion Image, SCION Corp). Patency was evaluated as the degree of in-stent stenosis by 
blinded histomorphometry and acute and chronic tissue response by blinded graded histopathology. 
The evaluated parameters were equivalent luminal diameter, neointimal thickness, percentage of lumen 
stenosis, total and mononucleocytes cellularity count. Furthermore injury and inflammation scores 
were appraised as described by Schwartz et al. (19) and Kornowski et al. (20) respectively. 
Discrepancies were resolved by mutual consensus.  
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Statistical analysis 
Histomorphometric variables of the proximal, mid and distal cross-sectional planes are reported as 
mean values per stent. Continuous variables, presented as means and standard deviations, were 
compared by Student’s t test for equality of means after a normalized distribution was assured. Box and 
whisker plots were computed to visualize medians and lower and higher quartiles. Categorical 
variables, presented as counts and percentages, were compared in cross tabulations tables by means of 
the Pearson chi-square test and likelihood ratio. The level of significance was taken as two-tailed 
p=0.05. All statistical analysis was performed with SPSS 11.5 (SPSS Inc).  
 
Results 
Overall analysis was conducted on 14 piglets. Twenty-five bare-metal stents were implanted preceded 
by angioplasty with a conventional balloon in 13 vessels and by the Genistein-eluted balloon in 12 
(Figure 1). None of the piglets presented clinical abnormalities during the study protocol.  
No untoward effects were reported comparing the histomorphometric and histopathologic measures of 
the vessels treated with Genistein-eluting (n=2) or conventional angioplasty balloon (n=1) one week 
after implantation (neointimal thickness 0.03 vs. 0.03, p=0.963; percentage of lumen stenosis 6.25 vs. 
5.43, p=0.550; mononucleocytes cellularity 261.0 vs. 271.0, p=0.976; injury score 0 in both groups).   
Ten target vessels were explanted at four weeks from implantation. Photomicrographs of the specimens 
at this time point disclosed universal healing and endothelialization in the stent struts (Figure 2). The 
histomorphometric and histopathologic measures comparing the target vessels treated with the 
Genistein-eluted balloon (n=4) with those treated with a conventional balloon (n=6) are reported in 
Table 1. Box and whisker plots are visualized in Figure 3. The Genistein-eluted balloon group 
disclosed a significant reduction, at four weeks from implantation, of the peri-stent inflammatory cells 
count (mononucleocytes 39±32 vs. 96±29 per square millimetre, p=0.019; Figure 4).   
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The remaining 12 target vessels were explanted from the piglets within six and eight weeks after the 
implantation. The histomorphometric and histopathologic measures comparing the vessels treated with 
Genistein-eluted (n=6) or conventional angioplasty balloon (n=6) are reported in Table 2. Box and 
whisker plots are visualized in Figure 5. The overall trends were towards a reduction of neointimal 
hyperplasia, of percentage of lumen stenosis, of the injury scores and of the count of inflammatory 
cells, without reaching nominal statistical significances. 
 
Discussion 
This study provides the first in vivo demonstration of the anti-inflammatory effect of a novel Genistein-
eluting balloon. In this porcine coronary artery model the tested device provided consistent data on 
safety and biofunctional efficacy. 
The coronary arteries of piglets have previously proved to respond in a similar manner to the human 
coronary arteries after injuries (21,22). In fact the in-stent neointimal thickness, usually caused within 
28 days from an injury, has been described as identical to the human restenotic neointima. The direct 
proportional correlation within this neointimal thickening and the degree of the injury has been an 
extremely relevant finding, permitting the creation of an injury-response regression relationship that 
quantities the response to the potential therapies (23). Given this evidence, the porcine coronary models 
using injuries caused by either stenting or overstretching alone are now accepted standards, by which 
potential restenosis therapies are studied.  
 
Despite the widespread use of intracoronary stents (20), in-stent restenosis remains a major clinical 
problem. In the attempt of achieving the ideal balance between healing and suppression of neointimal 
hyperplasia previous animal studies (19,25) have established a significant correlation between the 
degree of arterial injury caused by the metallic wire coils and the resultant neointimal thickness and 
lumen stenosis at the stented site. The restenosis and occlusion after initially successful percutaneous 
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procedures seem to be, in a large extent, due to the excessive formation of neointimal tissue in response 
to the unavoidable injury that occurs during balloon dilation and stent implantation. This process 
continues for weeks and months may finally result in the occlusion of the artery lumen. The mechanism 
driving this process after the initial phase of wound healing is yet not completely clear (26). In 
coronary arteries, however, excessive formation of neointima has been successfully inhibited by the 
implantation of drug-eluting stents, providing a platform for sustained drug release, which is believed 
to be a precondition of successful restenosis inhibition (27). Their implementation in clinical practice 
has however disclosed unexpected long-term results due to the delay in healing accompanied by the 
risk of late stent thrombosis (28,29).  
Few alternative methods have been tested to distribute specific drugs at the vessel wall sites. An 
angiographic contrast medium enriched with paclitaxel was found to be associated with an inhibition of 
neointimal proliferation four weeks after the intervention (30,31). Another interesting approach derives 
from the possibility of coating with antiproliferative drugs the balloons for angioplasty (32-34).  
On the other hand the inflammation, with subsequent release of chemotactic and growth factors after 
arterial injury, has been raised as one of the major contributing mechanisms of the restenosis (35,36). 
Despite the paucity of data indicating either causality or correlation between the degree of 
inflammation after arterial injury and the amount of neointimal formation Kornowski et al.(20) have 
delineated the role of inflammation in the neointimal formation within stents, with vast potential 
therapeutic implications. Indeed interventions focused on reducing inflammatory signalling carry the 
promise of attenuating restenosis without significantly delaying arterial healing. Only recently, the use 
of the oral corticosteroid prednisone after bare-metal stent deployment has yielded significant 
reductions in restenosis (16,37). Although these interesting results with oral corticosteroids following 
bare-metal stent deployment a large, multicentre analysis of a dexamethasone-eluting stent in patients 
with acute coronary syndromes offered a low rate of clinical events at six months, but no anti-
restenosis effect (17). 
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Given these presumptions we aimed to evaluate the effects of an anti-inflammatory drug-eluting 
balloon. The choice of the coated drug, Genistein, was based on the need of an officially approved and 
clinically safe agent, not presenting major cardiovascular side effects or common intolerances. 
Genistein, a phytoestrogen resembling 17β-estradiol, has been typically prescribed in women based on 
its ability, besides the anti-inflammatory effect, to positively regulate bone cell metabolism without 
harmful estrogenic activity in the breast and uterus (38). Furthermore in experimental studies Genistein 
has proved the ability to inhibit collagen-induced platelet aggregation, enhance NO production from the 
endothelium, decrease cell apoptosis, and inhibit neointima formation, proliferation and migration of 
vascular smooth muscular cells (39,40). 
The Genistein-eluting balloon proved safe. No untoward effects were found in any of the animals, 
including those sacrificed as early as one week post-PCI. An even more relevant finding was the 
universal healing and endothelialization in the stent struts within four weeks.  
Even more the tested device proved biological efficacy. The target coronary vessels treated with the 
Genistein-eluting balloon disclosed, at four weeks, a significant reduction in peri-stent inflammatory 
cells. This completely quantitative variable is certainly more reliable compared to the inflammatory 
score, especially in small sample populations as animal studies are. The lack of maintained evident 
anti-inflammatory effectiveness in the animals sacrificed within six and eight weeks does not surprise. 
As recently standardized, inflammation and healing in pigs coronary arteries suggests a time 
comparability of approximately 1 to 6 porcine to human, with pigs healing more rapidly (19). For this 
reason  the inflammatory process may, at this timepoint, be completely resolved. Furthermore the   
progressive elution of the drug may be close to finalized six-eight weeks from the implantation.  
In the clinical setting, the Genistein-eluting balloon holds the potential to limit inflammation and 
enhance earlier strut endothelialization following stenting. Further studies exploring the synergy of 
Genistein-eluting balloon followed by drug-eluting stent implantation are thus warranted. 
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In conclusion, this study is the first in vivo demonstration of the anti-inflammatory effects of a novel 
Genistein-eluting balloon, providing consistent data on safety and biofunctional efficacy of this device 
in a porcine coronary artery model. Local delivery of anti-inflammatory drugs before implantation of 
stents might indeed yield significant clinical benefits among patients with coronary artery disease.  
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Figure legends 
Figure 1. Description of the phases of study analysis (DEB, drug-eluted balloon; SB, standard 
angioplasty balloon). 
Figure 2. Sections perpendicular to the long axis of the vessel, at the position of the mid stent, 
implanted in a left anterior descending with the Genistein-eluted balloon (A) and in a right coronary 
artery with a conventional angioplasty balloon (B). In both these four weeks form implantation 
specimens healing and endothelialization appeared universal. The sections, 100mm thick, were stained 
with toulidine blue/haematoxylin and eosin/VVG. 
Figure 3. Box and whisker plots visualizing median, lower and higher quartiles for the variables 
analysed at four weeks from implantation, comparing the vessels treated with Genistein-eluted or 
conventional angioplasty balloon. In order from upper left to lower right neointimal thickness, 
percentage of lumen stenosis, injury score and mononucleocytes for square millimetre. P values by 
Student’s t test.  
Figure 4. Four weeks peri-stent cellularity in a left anterior descending implanted with the conventional 
angioplasty balloon (focus on total cellularity, A and on mononucleocytes, B) compared to a right 
coronary artery implanted with the Genistein-eluted balloon (focus on total cellularity, C and on 
mononucleocytes, D) with the arrows indicating mononucleocytes. The sections, 100mm thick, were 
stained with toulidine blue/haematoxylin and eosin/VVG. 
Figure 5. Box and Whisker plots visualizing median, lower and higher quartiles for the variables 
analysed at four weeks from implantation, comparing the vessels treated with Genistein-eluted or 
conventional angioplasty balloon. In order from upper left to lower right neointimal thickness, 
percentage of lumen stenosis, injury score and mononucleocytes for square millimetre. P values by 
Student’s t test.  
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Tables 
Table 1. Histomorphometric and histopathologic measures comparing the ten target vessels treated with 
Genistein-eluted or conventional angioplasty balloon explanted at four weeks from implantation (o.s., 
out of stent; i.s., intra-stent; MNCs, mononucleocytes).  
 DEB N Mean Standard 
deviation 
p-value 
Four weeks post-implantation      
Equivalent diameter o.s. prox no 6 1.67 0.11 0.205 
   yes 4 1.42 0.43  
 Equivalent diameter o.s. dist no 6 1.59 0.20 0.915 
   yes 4 1.61 0.17  
 Equivalent diameter i.s. average no 6 2.64 0.32 0.450 
   yes 4 2.47 0.37  
 Neointimal thickness average no 6 0.13 0.05 0.788 
   yes 4 0.14 0.06  
 % stenosis average no 6 18.77 5.79 0.319 
   yes 4 22.83 6.15  
 Injury score average no 6 0.11 0.17 0.630 
   yes 4 0.18 0.32  
 Cellularity x mm2 – total (10^6) no 6 5715.00 731.14 0.483 
   yes 4 5360.50 771.77  
 Cellularity x mm2 - MNCs no 6 95.83 28.94 0.019 
   yes 4 39.00 31.91  
 Inflammation score no 6 0.83 0.41 0.779 
   yes 4 0.75 0.50  
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Table 2. Histomorphometric and histopathologic measures comparing the twelve target vessels treated 
with Genistein-eluted or conventional angioplasty balloon explanted within six and eight weeks from 
implantation. Abbreviations as in Table 1.  
DEB N Mean Standard. 
deviation 
p-value 
Six-eight weeks post-implantation     
 Equivalent diameter o.s. prox no 6 1.68 0.41 0.342 
yes 6 1.46 0.33  
 Equivalent diameter o.s. dist no 6 1.44 0.57 0.628 
yes 6 1.59 0.47  
 Equivalent diameter i.s. average no 6 2.53 0.43 0.734 
yes 6 2.61 0.37  
 Neointimal thickness average no 6 0.14 0.089 0.835 
yes 6 0.13 0.11  
 % stenosis average no 6 21.66 11.23 0.534 
yes 6 17.68 10.16  
 Injury score average no 6 0.51 0.39 0.088 
yes 6 0.18 0.17  
 Cellularity x mm2 – total (10^6) no 6 4670.00 1197.31 0.362 
yes 6 5328.50 1192.03  
 Cellularity x mm2 - MNCs no 6 221.50 347.20 0.307 
yes 6 67.83 41.92  
 Inflammation score no 6 1.17 0.98 0.177 
yes 6 0.50 0.55  
  
 
 
 
